Lupin gains on getting USFDA’s approval for Fluoxetine Tablets

16 Apr 2019 Evaluate

Lupin is currently trading at Rs. 836.40, up by 6.20 points or 0.75% from its previous closing of Rs. 830.20 on the BSE.

The scrip opened at Rs. 831.05 and has touched a high and low of Rs. 843.95 and Rs. 827.10 respectively. So far 61199 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 986.00 on 10-Sep-2018 and a 52 week low of Rs. 720.40 on 28-Mar-2019.

Last one week high and low of the scrip stood at Rs. 843.95 and Rs. 799.40 respectively. The current market cap of the company is Rs. 37973.27 crore.

The promoters holding in the company stood at 46.98%, while Institutions and Non-Institutions held 38.84% and 14.18% respectively.

Lupin has received approval for its Fluoxetine Tablets USP, 10 mg and 20 mg, from the United States Food and Drug Administration (USFDA) to market a generic version of Eli Lilly and company’s (Eli Lilly) Prozac Tablets, 10 mg and 20 mg.

The company’s Fluoxetine Tablets USP, 10 mg and 20 mg, is the generic version of Eli Lilly’s Prozac Tablets, 10 mg and 20 mg. Fluoxetine Tablets, 10 mg and 20 mg, (RLD: Prozac) had annual sales of approximately $68.2 million in the US (IQVIA MAT December 2018).

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.

Lupin Share Price

2111.95 22.30 (1.07%)
17-Dec-2025 15:14 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1795.00
Dr. Reddys Lab 1272.55
Cipla 1496.30
Zydus Lifesciences 917.95
Lupin 2111.95
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×